Menu
Faculty
-
Parkinson's Disease: Treatment Guideline Update, 2010-2011
C. Warren Olanow, MD, FRCPC, Moderator
Disclosure:
Consultant: Ceregene, Inc., Merck Serono International, SA, Novartis, Abbot Pharmaceuticals, Inc., Lundbeck, and Teva Neuroscience
Speaker: Teva Neuroscience
-
Kapil D. Sethi, MD, FRCP, Panelist
Disclosure:
Consulting / Speaker's Bureau: Boehringer Ingelheim, Glaxo Smithkline, Ipsen, Novartis, Teva Neuroscience
-
Matthew B. Stern, MD, Panelist
Disclosure:
Consultant: Adamas Pharmaceuticals, Inc, Ipsen, Novartis Pharmaceuticals, Merck, Teva Neuroscience
Speaker: Teva Neuroscience
-
Parkinson's Disease: Current Concepts & Treatment Strategies 2010
C. Warren Olanow, MD, FRCPC, Moderator
Disclosure:
Consultant: Boehringer Ingelheim, Ceregene, Inc., Ipsen, Merck Serono International, SA, Novartis, Solvay Pharmaceuticals, Inc., Schering Plough, and Teva Neuroscience
Stock options: Ceregene -
Matthew B. Stern, MD
Disclosure:
Consultant: Adamas Pharmaceuticals, Inc, Boehringer Ingelheim, Ipsen, Novartis Pharmaceuticals, NuPathe, Inc., Schering-Plough -
Kapil D. Sethi, MD, FRCP
Disclosure:
Consulting / Speaker's Bureau: Boehringer Ingelheim, Glaxo Smithkline, Ipsen, Novartis, Teva Neuroscience, UCB Pharma
Stockholder: Elan, Pfizer -
Karl Kieburtz, MD, MPH
Disclosure:
Safety Committee: Abbott, Lilly, Merz, Schering Plough
Research Support: Boehringer Ingelheim, NeuroSearch, Medivation, Inc.
Consultant: Antipodean Pharmaceuticals, Eisai, FoldRx, Impax Pharmaceuticals, Ipsen, Lundbeck A/S, Prestwick Pharmaceuticals, Teva Neuroscience, XenoPort
Steering Committee of a Clinical Trial: Ceregene, Novartis, Solvay
